For select adult patients with mild hyperglycemia and type 2 diabetes, the guideline suggests using either a DPP4 inhibitor with correction insulin or scheduled insulin therapy. Trigger phrase: "Patient has mild hyperglycemia and T2D, could we use a DPP4i?"
Scanned 9/9/2026
Install to Claude Code
npx -y skills add dromlakhani/MD2SKILL --skill es-dpp4i-select-patients --agent claude-codeInstalls into .claude/skills of the current project.
Are you the author of Es Dpp4i Select Patients?
Add the live security badge to your README — it updates automatically with every re-scan.
[](https://www.skillsdirectory.com/skills/dromlakhani-es-dpp4i-select-patients)More formats (shields.io, HTML) on the badges page.
---
name: es-dpp4i-select-patients
description: For select adult patients with mild hyperglycemia and type 2 diabetes, the guideline suggests using either a DPP4 inhibitor with correction insulin or scheduled insulin therapy. Trigger phrase: "Patient has mild hyperglycemia and T2D, could we use a DPP4i?"
---
# Consider DPP4i with correction insulin or scheduled insulin for select patients with mild hyperglycemia and type 2 diabetes
## STEP 1 — Gather Information
Confirm type 2 diabetes (not T1D or other insulin-dependent diabetes). Assess admission blood glucose (BG) <180 mg/dL, recent HbA1c <7.5% (9.4 mmol/L). If patient was on insulin before hospitalization, verify total daily insulin dose <0.6 units/kg/day.
## STEP 2 — Rule In / Rule Out
Rule out if patient has type 1 diabetes, BG ≥180 mg/dL, HbA1c ≥7.5%, or (if on pre-admission insulin) total daily insulin dose ≥0.6 units/kg/day. If any exclusion applies, do not proceed with DPP4i strategy.
## STEP 3 — Classify or Stratify
If patient meets all inclusion criteria (T2D, BG <180 mg/dL, HbA1c <7.5%, and appropriate insulin dose if applicable), classify as a select patient suitable for DPP4i‑based approach.
## STEP 4 — Decide
Initiate either a DPP4 inhibitor (e.g., sitagliptin 100 mg daily) plus correction insulin (sliding scale) for intermittent hyperglycemia, OR start scheduled insulin therapy (basal ± bolus) if preferring insulin monotherapy. Re‑evaluate BG; if persistently >180 mg/dL on DPP4i, switch to scheduled insulin.
## Clinical Guardrails / Mimics / Pitfalls
Do not use in T1D or insulin‑dependent diabetes. Avoid if admission BG ≥180 mg/dL or HbA1c ≥7.5%. If BG remains >180 mg/dL despite DPP4i, discontinue DPP4i and initiate scheduled insulin. Counsel on cost and discharge planning if continuing DPP4i post‑hospitalization.
## Concrete Clinical Example
A 66‑year‑old woman with T2D, home metformin, admission BG 148 mg/dL, HbA1c 7.0%, no home insulin. Meets criteria. Prescribe sitagliptin 100 mg daily plus correction insulin lispro 2 units for BG 150‑180, 4 units for 181‑250, 6 units for >250 mg/dL before meals.
**Source:** Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2022, https://doi.org/10.1210/clinem/dgac278
Is this your skill, or is something wrong with this listing? Request removal or report an issue. Author removals are honored within 72 hours.
No comments yet. Be the first to comment!